Glucose-lowering medications have been the mainstay of managing type 2 diabetes for 20 years. But a recent polemic between diabetes organisations has prompted an examination of specific targets for blood sugar in different patients. The podcast also summarises the use of new drug classes that don’t just lower blood glucose but appear to provide cardiovascular benefits directly in sicker patients.
Guests: Professor Sophia Zoungas FRACP (Monash Health; Board Director, Diabetes Australia; Clinical Director, National Association of Diabetes Centres); Dr Paul Drury FRACP (Clinical Advisor in Diabetes, Ministry of Health; University of Auckland)[Case Report] 68yo with cardiometabolic risk factors and transient monocular vision loss
[Journal Club] Baricitinib immune therapy for new onset type 1 diabetes
Ep106: The whiskey fix and the apple of Granada
Ep105: When parents and paediatrics clash
[IMJ On-Air] Is the jury still out on omega-3 supplementation?
[IMJ On-Air] HepatoCare: a model for palliative and supportive care in advanced cirrhosis
Ep102: Staying on script with semaglutide
Ep101: Setting the standard for workforce wellbeing
Ep100: Conversations with ChatGPT
Ep99: When AI goes wrong
[IMJ On-Air] A tiger in the mallee: Victoria’s JEV cluster
Ep97: The governance of AI
Ep96: The ergonomics of AI
Ep95: Machine Learning 101
Ep94: Facing up to racial bias
Ep93: The rise and fall of mpox
Ep92: Data-driven practice improvement
[IMJ On-Air] Hyperglycaemia and COVID-19
[IMJ On-Air] High readmission rates in cirrhotic patients
Ep89: What we know about long COVID
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Peter Attia Drive
The Doctor’s Farmacy with Mark Hyman, M.D.